News | November 20, 2019

Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis – MOMENTUM trial designed to confirm the unique benefits of momelotinib on all three hallmarks of myelofibrosis: symptoms, anemia and enlarged spleen – –...

News | November 7, 2019

Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants VANCOUVER, Nov. 7, 2019 /CNW/ – Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and...